Drugs targeting the renin–angiotensin–aldosterone system

[1]  C. Jones,et al.  Myogenic and flow-dependent control mechanisms in the coronary microcirculation , 1993, Basic Research in Cardiology.

[2]  M. Nakashima,et al.  Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects , 2004, European Journal of Clinical Pharmacology.

[3]  N. Hollenberg,et al.  Literature alert , 2002 .

[4]  A. Pessina,et al.  Biological properties of the angiotensin peptides other than angiotensin II: implications for hypertension and cardiovascular diseases , 2002, Journal of hypertension.

[5]  H. Brunner,et al.  The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview , 2002, Journal of Human Hypertension.

[6]  E. Burgess,et al.  P-70: The selective aldosterone blocker eplerenone is safe and efficacious for the long-term treatment of mild-to-moderate hypertension , 2002 .

[7]  A. Stanton,et al.  P-67: Dose response antihypertensive efficacy of aliskiren (SPP 100), an orally active renin inhibitor , 2002 .

[8]  Steven Snapinn,et al.  Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol , 2002, The Lancet.

[9]  M. Nieminen,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[10]  A. Lincoff,et al.  The role of spironolactone in the treatment of patients with refractory hypertension. , 2001, American journal of hypertension.

[11]  G. Sagnella.  Vasopeptidase inhibitors. , 2002, Journal of the renin-angiotensin-aldosterone system : JRAAS.

[12]  R. Simpson,et al.  Evidence That the Angiotensin IV (AT4) Receptor Is the Enzyme Insulin-regulated Aminopeptidase* , 2001, The Journal of Biological Chemistry.

[13]  B. Lévy,et al.  Physiological and Pathophysiological Functions of the AT2 Subtype Receptor of Angiotensin II: From Large Arteries to the Microcirculation , 2001, Hypertension.

[14]  B. Lévy,et al.  Physiological and Pathophysiological Functions of the AT2 Subtype Receptor of Angiotensin II: From Large Arteries to the Microcirculation , 2001, Hypertension.

[15]  J. Rouleau,et al.  Vasopeptidase Inhibitors: A New Therapeutic Concept in Cardiovascular Disease? , 2001, Circulation.

[16]  A. Chiu,et al.  Angioedema Associated With Angiotensin II Receptor Antagonists: Challenging Our Knowledge of Angioedema and Its Etiology , 2001, The Laryngoscope.

[17]  Paul Bebbington,et al.  The World Health Report 2001 , 2001, Social Psychiatry and Psychiatric Epidemiology.

[18]  D. Johnston.  Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack , 2001, The Lancet.

[19]  B. Brenner,et al.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.

[20]  H. Parving,et al.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. , 2001, The New England journal of medicine.

[21]  E. Lewis,et al.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.

[22]  S G Chrysant,et al.  Comparative Efficacy of Olmesartan, Losartan, Valsartan, and Irbesartan in the Control of Essential Hypertension , 2001, Journal of clinical hypertension.

[23]  P. Penar,et al.  Protection against ischemia: a physiological function of the renin-angiotensin system. , 2001, Biochemical pharmacology.

[24]  C. Schmid,et al.  Angiotensin-Converting Enzyme Inhibitors and Progression of Nondiabetic Renal Disease , 2001, Annals of Internal Medicine.

[25]  G. Schillaci,et al.  [Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomized trials]. , 2001, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.

[26]  Keith C. Norris,et al.  Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. , 2001, JAMA.

[27]  H. Koike,et al.  In vitro and in vivo pharmacology of olmesartan medoxomil, an angiotensin II type AT1 receptor antagonist , 2001, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[28]  G. Viberti,et al.  O-6: Microalbuminuria reduction with valsartan , 2001 .

[29]  J. Sayers.  The world health report 2001 - Mental health: new understanding, new hope , 2001 .

[30]  B Neal,et al.  Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials , 2000, The Lancet.

[31]  F. Alla,et al.  Limitation of Excessive Extracellular Matrix Turnover May Contribute to Survival Benefit of Spironolactone Therapy in Patients With Congestive Heart Failure: Insights From the Randomized Aldactone Evaluation Study (RALES) , 2000, Circulation.

[32]  D. Silversides,et al.  Contribution of circulating renin to local synthesis of angiotensin peptides in the heart. , 2000, Physiological genomics.

[33]  G. Bakris,et al.  Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[34]  K. Catt,et al.  International union of pharmacology. XXIII. The angiotensin II receptors. , 2000, Pharmacological reviews.

[35]  B. Pitt,et al.  The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure , 2000 .

[36]  G. Schulman.  Hypertension: A Companion to Brenner and Rector's The Kidney , 2000, Annals of Internal Medicine.

[37]  Bertram Pitt,et al.  Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II , 2000, The Lancet.

[38]  C. Delcayre,et al.  Cardiac aldosterone production and ventricular remodeling. , 2000, Kidney international.

[39]  B. Williams,et al.  Angiotensin II antagonists for hypertension: are there differences in efficacy? , 2000, American journal of hypertension.

[40]  C. Rapezzi.  [Comparison of candesartan, enalapril and their combination in congestive heart failure]. , 2000, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.

[41]  T. Unger.  The angiotensin type 2 receptor: variations on an enigmatic theme. , 1999, Journal of hypertension.

[42]  T. Hedner,et al.  Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study , 1999, The Lancet.

[43]  J. Siché,et al.  ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension , 1999, Journal of Human Hypertension.

[44]  S. Yusuf,et al.  Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. , 1999, Circulation.

[45]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[46]  K. Weber,et al.  Extra-adrenal mineralocorticoids and cardiovascular tissue. , 1999, Journal of molecular and cellular cardiology.

[47]  D. Vaughan,et al.  Bradykinin stimulates tissue plasminogen activator release in human vasculature. , 1999, Hypertension.

[48]  D. Levy,et al.  Trends in the prevalence of hypertension, antihypertensive therapy, and left ventricular hypertrophy from 1950 to 1989. , 1999, The New England journal of medicine.

[49]  T. Bunt.  An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan. , 1999, Clinical therapeutics.

[50]  L. Niskanen,et al.  Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial , 1999, The Lancet.

[51]  D. Harrison,et al.  Superoxide production, risk factors, and endothelium-dependent relaxations in human internal mammary arteries. , 1999, Circulation.

[52]  S. Oparil,et al.  Effects of candesartan cilexetil in patients with severe systemic hypertension. Candesartan Cilexetil Study Investigators. , 1998, The American journal of cardiology.

[53]  D. Vaughan,et al.  Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1. , 1998, Hypertension.

[54]  J. Morrow,et al.  Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. , 1998, The New England journal of medicine.

[55]  R. Collins,et al.  Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group. , 1998, Circulation.

[56]  S. Neldam,et al.  The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan. , 1998, Blood pressure.

[57]  S. Oparil,et al.  Effects of candesartan cilexetil in patients with systemic hypertension. Candesartan Cilexetil Study Investigators. , 1998, The American journal of cardiology.

[58]  S. Oparil,et al.  Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations. , 1997, American journal of physiology. Heart and circulatory physiology.

[59]  A. Levey,et al.  Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group. , 1997, Annals of internal medicine.

[60]  S. Oparil,et al.  Compartmentalization of angiotensin II generation in the dog heart. Evidence for independent mechanisms in intravascular and interstitial spaces. , 1997, The Journal of clinical investigation.

[61]  Bertram Pitt,et al.  Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE) , 1997, The Lancet.

[62]  H. Drexler,et al.  Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. , 1997, Circulation.

[63]  W. Kiowski,et al.  Functional and biochemical analysis of angiotensin II-forming pathways in the human heart. , 1997, Circulation research.

[64]  Detection.  The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI) , 1997 .

[65]  R. Weinshilboum,et al.  The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. , 1997, Archives of internal medicine.

[66]  Y. Ohgami,et al.  Transient upregulation of the AT2 receptor mRNA level after global ischemia in the rat brain , 1996, Neuropeptides.

[67]  B. Lévy,et al.  Chronic blockade of AT2-subtype receptors prevents the effect of angiotensin II on the rat vascular structure. , 1996, The Journal of clinical investigation.

[68]  K. Catt,et al.  Angiotensin receptors and their antagonists. , 1996, The New England journal of medicine.

[69]  J. Ménard,et al.  Bradykinin pathway is involved in acute hemodynamic effects of enalaprilat in dogs with heart failure. , 1996, The American journal of physiology.

[70]  R. Schmieder,et al.  Reversal of Left Ventricular Hypertrophy in Essential Hypertension: A Meta-analysis of Randomized Double-blind Studies , 1996 .

[71]  Michael A. Proschan,et al.  Rationale and Design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) , 1996 .

[72]  M. Lishner,et al.  Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study. , 1996, Archives of internal medicine.

[73]  S. Karnik,et al.  Angiotensin II-Forming Activity in a Reconstructed Ancestral Chymase , 1996, Science.

[74]  D. Vaughan,et al.  Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. , 1995, The Journal of clinical investigation.

[75]  J. Bauer,et al.  The angiotensin II type 1 receptor antagonists. A new class of antihypertensive drugs. , 1995, Archives of internal medicine.

[76]  Pats-Collaborating-Group-.  Post-stroke antihypertensive treatment study. A preliminary result , 1995 .

[77]  B Bornkessel,et al.  [Angiotensin II receptor antagonists]. , 1995, Medizinische Monatsschrift fur Pharmazeuten.

[78]  J. Funder.  Mineralocorticoid receptors and hypertension , 1995, The Journal of Steroid Biochemistry and Molecular Biology.

[79]  S. Yusuf,et al.  Overview of Randomized Trials of Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Patients With Heart Failure , 1995 .

[80]  P. Timmermans,et al.  Proposed update of angiotensin receptor nomenclature. , 1995, Hypertension.

[81]  D. Vaughan,et al.  Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis. , 1995, The Journal of clinical investigation.

[82]  J. Swales.  Manual of Hypertension , 1995 .

[83]  Pats,et al.  Post-stroke antihypertensive treatment study. A preliminary result. , 1995, Chinese medical journal.

[84]  G. Leonetti,et al.  Choosing the right ACE inhibitor. A guide to selection. , 1995, Drugs.

[85]  J. Wicke,et al.  Angiotensin AT2 receptor stimulation increases survival in gerbils with abrupt unilateral carotid ligation. , 1994, Journal of cardiovascular pharmacology.

[86]  A. Bénétos,et al.  Effects of bradykinin B2 receptor antagonism on the hypotensive effects of ACE inhibition , 1994, British journal of pharmacology.

[87]  S. Yusuf,et al.  Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. , 1994, Circulation.

[88]  R W Alexander,et al.  Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. , 1994, Circulation research.

[89]  A Fournier,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. , 1994, The New England journal of medicine.

[90]  H. Sasamura,et al.  Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors , 1995, The Journal of biological chemistry.

[91]  C. Halstenson,et al.  New Therapeutic Agents in the Management of Hypertension: Angiotensin II-Receptor Antagonists and Renin Inhibitors , 1993, The Annals of pharmacotherapy.

[92]  R. Bain,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. , 1993 .

[93]  R. Bain,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. , 1993, The New England journal of medicine.

[94]  A. Husain.  The chymase-angiotensin system in humans. , 1993, Journal of hypertension.

[95]  P. Kang,et al.  Angiotensin II Receptor Blockade: An Innovative Approach to Cardiovascular Pharmacotherapy , 1993, Journal of clinical pharmacology.

[96]  P. Ridker,et al.  Stimulation of Plasminogen Activator Inhibitor In Vivo by Infusion of Angiotensin II Evidence of a Potential Interaction Between the Renin‐Angiotensin System and Fibrinolytic Function , 1993, Circulation.

[97]  V. Dzau.  Local expression and pathophysiological role of renin-angiotensin in the blood vessels and heart. , 1993, Basic research in cardiology.

[98]  F. Suzuki,et al.  [Renin-angiotensin system]. , 1992, Nihon rinsho. Japanese journal of clinical medicine.

[99]  K. Weber,et al.  Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. , 1992, The Journal of laboratory and clinical medicine.

[100]  S. Oparil,et al.  Converting-enzyme inhibitors increase converting-enzyme mRNA and activity in endothelial cells. , 1992, The American journal of physiology.

[101]  S. Yusuf,et al.  Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. , 1992, The New England journal of medicine.

[102]  W. Linz,et al.  A specific B2‐bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramipril , 1992, British journal of pharmacology.

[103]  N. Aiyar,et al.  Cloning and characterization of a human angiotensin II type 1 receptor. , 1992, Biochemical and biophysical research communications.

[104]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[105]  F. Tristani,et al.  A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. , 1991, The New England journal of medicine.

[106]  J. Laragh,et al.  Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. , 1991, The New England journal of medicine.

[107]  F. Messerli.  Cardiovascular Drug Therapy , 1996 .

[108]  S. Matalon,et al.  Endogenous xanthine oxidase-derived O2 metabolites inhibit surfactant metabolism. , 1990, The American journal of physiology.

[109]  N. Niedermaier,et al.  Cardiac angiotensinogen and its local activation in the isolated perfused beating heart. , 1990, Circulation research.

[110]  G. Mugesh,et al.  Converting-enzyme inhibitors in the treatment of hypertension. , 2011, The New England journal of medicine.

[111]  A. LaCroix,et al.  Antihypertensive Drug Therapy and Survival by Treatment Status in a National Survey , 1989, Hypertension.

[112]  D. Ganten,et al.  Converting enzyme inhibition specifically prevents the development and induces regression of cardiac hypertrophy in rats. , 1989, Clinical and experimental hypertension. Part A, Theory and practice.

[113]  David R. Williams.  Book ReviewHuman Gene Therapy , 1988 .

[114]  G. Lamas,et al.  Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. , 1988, The New England journal of medicine.

[115]  K. Swedberg,et al.  Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1988, The American journal of cardiology.

[116]  J. Ménard,et al.  Efficacy and tolerance of spironolactone in essential hypertension. , 1987, The American journal of cardiology.

[117]  T. Brody,et al.  A comparative study of the distributions of renin and angiotensinogen messenger ribonucleic acids in rat and mouse tissues. , 1987, Endocrinology.

[118]  J. Wood,et al.  Inhibitors of renin as potential therapeutic agents. , 1987, Journal of enzyme inhibition.

[119]  Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1987, The New England journal of medicine.

[120]  J. Biollaz,et al.  Antihypertensive Therapy with MK 4211: Angiotensin II‐Renin Relationships to Evaluate Efficacy of Converting Enzyme Blockade , 1982, Journal of cardiovascular pharmacology.

[121]  W F Ganong,et al.  The renin-angiotensin system. , 1978, Annual review of physiology.

[122]  B Rubin,et al.  Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents. , 1977, Science.

[123]  S. Oparil,et al.  The renin-angiotensin system (first of two parts). , 1974, The New England journal of medicine.

[124]  J. Laragh,et al.  Essential hypertension: renin and aldosterone, heart attack and stroke. , 1972, The New England journal of medicine.

[125]  T. Goodfriend,et al.  Angiotensin Receptors , 1994, Springer US.

[126]  S. Ferreira.  A Bradykinin-Potentiating Factor (BPF) present in the Venom of Bothrops jararaca. , 1965 .

[127]  L. Skeggs,et al.  THE PREPARATION, PURIFICATION, AND AMINO ACID SEQUENCE OF A POLYPEPTIDE RENIN SUBSTRATE , 1957, The Journal of experimental medicine.